NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Independence Blue Cross has agreed to cover Interpace's thyroid tests, ThyGeNext and ThyraMir, for patients with thyroid cancer.
Independence covers about 2.5 million individuals in Philadelphia and Southeastern Pennsylvania.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.